Independent · non-commercial · publishes on a quarterly cycle|Current cycle 2026 Q3
Compound Evidence InstituteEvidence synthesis · established 2023Graded assessments of compounds, trials, methods and supply
Document set current to 30 July 2026
Indication assessment · Dermatological

Cutaneous wound healing and tissue repair — indication assessment

Restoration of epithelial and dermal integrity following injury, assessed by closure rate, area reduction and scar quality.

Document identifier
CEI-IN-23
Series
Indication assessment
Version
2.2
Published
08 Jan 2025
Last reviewed
08 Jan 2025
Next review
08 Jan 2027
Identifier
10.71829/cei.ind.23
Certainty
Not rated
Cycle
2025 Q1
ICD-11
ND56
Category
Dermatological

§1Assessment

§1.1Definition

Restoration of epithelial and dermal integrity following injury, assessed by closure rate, area reduction and scar quality.

§1.2Anchor and additional outcomes

The Institute designates one anchor outcome per indication so that estimates for different compounds are reported on a common measure. The anchor for this indication is the first outcome below.

  1. Time to complete closure
  2. Percentage area reduction
  3. Scar assessment scale
  4. Infection rate

§1.3State of the evidence

Distribution of certainty ratingsShare of assessed outcomes at each certainty level.7compounds
HighModerateLowVery low
Figure 1. Certainty ratings across the 7 compounds the Institute assesses for this indication. A high rating for one compound says nothing about another.

The Institute assesses 7 compounds in this indication, drawing on 30 trial records and 6 evidence syntheses. No compound is graded above low certainty in this indication, which the Institute records as the principal finding for it.[1,2]

References cited on this page

References are numbered in order of first citation in this document. Each superscript in the text links to its entry below.

  1. Pickart L, Margolina A. Regenerative and protective actions of the GHK-Cu peptide in the light of the new gene data. International Journal of Molecular Sciences 2018;19(7):1987. doi:10.3390/ijms19071987 · PMID 29986520
  2. D’Hondt M, Bracke N, Taevernier L, Gevaert B, Verbeke F, Wynendaele E, De Spiegeleer B. Related impurities in peptide medicines. Journal of Pharmaceutical and Biomedical Analysis 2014;101:2–30. doi:10.1016/j.jpba.2014.06.012 · PMID 25044089

Identifiers are reproduced only where the Institute holds them. Where a digital object identifier or PubMed identifier is not shown, the Institute has recorded the journal and year and has not constructed an identifier.

Nothing published by the Institute is medical advice, a diagnosis, a prescription, a treatment recommendation or a purchasing recommendation. Compounds supplied for research use are not approved for human or veterinary use in any jurisdiction, and a favourable analytical assessment of a supplier is not a statement that any product is safe or effective. The Institute publishes certainty ratings and never recommendations. No telephone number, messaging handle or ordering channel appears anywhere on this site.